Skip to content
Corporate VCAllocates capital directlyActive · deal in last 18 monthsLAST VERIFIED Oct 2026 · 9 SOURCES

BNP Paribas Développement

Minority private equity and venture subsidiary investing the own funds of BNP Paribas

BNP Paribas subsidiary investing the bank's own funds (evergreen) as a minority shareholder in French SMEs, mid-caps and startups; €2.3bn portfolio at end-2025, 600+ holdings.

HEADQUARTERS
Paris, France
FOUNDED
—
AUM
€2.3B (2025)
OUTSIDE CAPITAL
No — own capital only
TEAM LISTED
15 people

FOCUS

STAGES
SeedSeries ASeries BGrowthBuyout
SECTORS
HealthTechDeep TechClimate & EnergySoftware & SaaSIndustrial & Manufacturing
ASSET MIX
Private equityVenture capitalDirect investments
GEOGRAPHY
France

WHAT IT IS

Corporate VC. A corporation investing from its own balance sheet, usually with strategic goals.

ABOUT

BNP Paribas Développement is a subsidiary of the BNP Paribas group that has invested its own funds for more than 38 years as a minority shareholder in French SMEs and mid-sized companies, for development capital, shareholder reorganisations and transmissions. Since 2016 a dedicated venture team has also invested in startups and scale-ups from seed onwards, mainly in healthtech, deeptech, ecological transition, digital and cybersecurity. Its website reports a portfolio of more than 600 holdings, €2.3bn of outstanding investments at end-2025 and €304M invested in 2025. Its investment team of about 50 works from Paris and regional offices across mainland France and the French overseas departments.

INVESTMENT THESIS

Minority, evergreen equity and quasi-equity in profitable French SMEs and mid-caps (revenue typically €10M–€1bn), €1M–€20M per deal (first tickets €2M–€15M), holding 3–10 years; venture tickets of €0.5M–€3M at seed, Series A and beyond as follower or co-lead in healthtech, deeptech, ecological transition, digital and cybersecurity startups in France.

PORTFOLIO (12)

  • WithingsNOTABLE
    HealthTech
  • MedincellNOTABLE
    Biotech & Life Sciences
  • TissiumNOTABLE
    HealthTech
  • KinéisNOTABLE
    Space
  • Synapse Medicine
    HealthTech
  • TreeFrog Therapeutics
    Biotech & Life Sciences
  • Inbolt
    Deep Tech
  • C12 Quantum Electronics
    Deep Tech
  • Mecaware
    Climate & Energy
  • Air Support
    Industrial & Manufacturing
  • Chausson Matériaux
  • Jardel
    Mobility & Logistics

TEAM

  • Philippe Molas
    Chief Executive Officer (Directeur Général) · source
  • Jean-Charles Moulin
    Deputy CEO (Directeur Général Délégué) · source
  • Pauline Allary
    Deputy CEO (Directrice Générale Déléguée) · source
  • Delphine Larrandaburu
    Director; Vice-President of France Invest · source
  • Yannick Carré
    Director · source
  • Patrice Vandenbossche
    Director · source
  • Gilles Poncet
    Director · source
  • David Lardey
    Secretary General · source
  • Rhema Amaddoune
    Chief Financial Officer · source
  • Nicolas Tymen
    Director of Holdings, Venture · source
  • Sophie Pierrin-Lepinard
    Director of Holdings, Venture – Healthtech · source
  • David Moreau
    Investment Director, Venture – Healthtech · source
  • Thomas Bourlot
    Investment Director, Venture · source
  • Patricia Leyrat
    Investment Director, Venture · source
  • Lucas Scherrer
    Head of Sustainability · source

LINKS

FAQ

BNP Paribas Développement is a corporate venture arm based in Paris, France.

Yes. BNP Paribas Développement invests directly in private companies.

BNP Paribas Développement invests at Seed, Series A, Series B, Growth and Buyout stages in HealthTech, Deep Tech, Climate & Energy, Software & SaaS and Industrial & Manufacturing.

BNP Paribas Développement's stated ticket size is €500K–€20M.

Key people at BNP Paribas Développement include Philippe Molas (Chief Executive Officer (Directeur Général)), Jean-Charles Moulin (Deputy CEO (Directeur Général Délégué)), Pauline Allary (Deputy CEO (Directrice Générale Déléguée)) and Delphine Larrandaburu (Director; Vice-President of France Invest).

BNP Paribas Développement's investments include Withings, Medincell, Tissium, Kinéis, Synapse Medicine, TreeFrog Therapeutics, Inbolt and C12 Quantum Electronics, among others.

The most recent publicly reported investment by BNP Paribas Développement is Inbolt (€11M round led by Shift4Good (follow-on as existing investor)), announced in Sep 2026.

No. BNP Paribas Développement invests its own capital and does not raise money from outside investors.